P0892 - Underrepresentation of Minorities in the Major Biologics Trials for Crohn's Disease

Anvit D. Reddy, DO¹, Nadim A. Qadir, DO², Landen Shane Burstiner, DO, MSc¹, Lauren N.. Stemboroski, DO^1
1University of Florida College of Medicine, Jacksonville, FL; ²University of Florida College of Medicine, Windermere, FL

Introduction: Historically, Inflammatory Bowel Disease (IBD) was thought to predominantly affect people of Western European descent, however, this notion has changed as the incidence of IBD has been shown to grow globally. The estimated incidence of IBD per 100,000 people extrapolated from 2020 United States Census data was 812 for Whites, 504 for Blacks, 403 for Asians, and 458 for Hispanics. The purpose of this study was to evaluate if patients studied in trials for biologics in Crohn’s Disease (CD) reflected the changing incidence of IBD globally.

Methods: Major trials for biologics data were reviewed via web-based records from 2002 to the present. Patient characteristic data was analyzed and extracted manually (Table 1).

Results: Of the 14 studies reviewed, 7 had a % Whites rate over 75 with 3 not reporting patient characteristics. In the 5 studies that took place in 2022 and beyond, 4/5 had a % Whites rate of less than 75. The average number of countries involved in trials increased from 11.7 in the early 2000s to 35.5 in the 2020s.

Discussion: All biologics were studied multi-nationally, however, a closer look at subject characteristics revealed a skew towards White subjects. In some cases, such as with large trials for adalimumab, race characteristics were not reported in their publications. Upadactinib and Riskanizumab are newer biologics that have been studied within the last five years. Their subject characteristics included more non-white representation, however, the proportion of non-whites studied still does not reflect the change in incidence for non-white patients in the United States. In conclusion, although recent studies have included more subjects from non-white races, there still is a misrepresentation of non-white races in IBD medication data. Future medications targeting IBD management should aim to include diverse subject data from global populations to accurately reflect the changing incidence of IBD.


Disclosures:


Anvit D. Reddy, DO¹, Nadim A. Qadir, DO², Landen Shane Burstiner, DO, MSc¹, Lauren N.. Stemboroski, DO¹. P0892 - Underrepresentation of Minorities in the Major Biologics Trials for Crohn's Disease, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.